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Conserved collateral antibiotic susceptibility
networks in diverse clinical strains of Escherichia coli
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There is urgent need to develop novel treatment strategies to reduce antimicrobial resistance.
Collateral sensitivity (CS), where resistance to one antimicrobial increases susceptibility to
other drugs, might enable selection against resistance during treatment. However, the suc-
cess of this approach would depend on the conservation of CS networks across genetically
diverse bacterial strains. Here, we examine CS conservation across diverse Escherichia coli
strains isolated from urinary tract infections. We determine collateral susceptibilities of
mutants resistant to relevant antimicrobials against 16 antibiotics. Multivariate statistical
analyses show that resistance mechanisms, in particular efﬂux-related mutations, as well as
the relative ﬁtness of resistant strains, are principal contributors to collateral responses.
Moreover, collateral responses shift the mutant selection window, suggesting that CS-
informed therapies may affect evolutionary trajectories of antimicrobial resistance. Our data
allow optimism for CS-informed therapy and further suggest that rapid detection of resis-
tance mechanisms is important to accurately predict collateral responses.
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The evolution and increasing prevalence of antimicrobialresistance is driven by the consumption and misuse ofantimicrobials in human medicine, agriculture, and the
environment1–3. Historically, the threat of antimicrobial resis-
tance was overcome by using novel antimicrobials with unique
drug targets. However, the discovery rate of new antimicrobial
agents has dwindled4–6 and severely lags behind the rate of
resistance evolution7. While concerted scientiﬁc, corporate, and
political focus is needed to recover antimicrobial pipelines8–10,
there is an urgent need for alternative strategies that prolong the
efﬁcacy of existing antimicrobials and prevent or slow the
emergence, spread, and persistence of antimicrobial resistance.
Current global efforts to improve antimicrobial stewardship lar-
gely focus on reducing overall antimicrobial consumption and
increasing awareness of resistance development9,11–13. While
these efforts will affect the evolution and spread of resistance,
mounting evidence suggests that these changes alone will not lead
to large-scale reductions in the occurrence of antimicrobial
resistance14–18.
Several recent studies have examined novel treatment strategies
using multiple antimicrobials that could reduce the rate of
resistance emergence and even reverse pre-existing resistance.
These approaches, collectively termed selection inversion strate-
gies, refer to cases where resistance becomes costly in the pre-
sence of other antimicrobial agents19. Among the most promising
of these strategies are those based on a phenomenon ﬁrst reported
in 1952, termed collateral sensitivity (CS), where resistance to one
antimicrobial simultaneously increases the susceptibility to
another20. CS and its inverse, cross-resistance (CR), have been
demonstrated for several bacterial species and across different
classes of antimicrobials21–27. These results have formed the basis
of proposed CS-informed antimicrobial strategies that combine
drug pairs22,28 or alter temporal administration, e.g. drug
cycling21,29. CS-informed strategies would force bacteria to evolve
resistance along a predictable trajectory, resulting in CS; this
predictability could be exploited to ultimately reverse resistance
and prevent the ﬁxation of resistance and multi-drug resistance
development at the population level of bacterial communities.
Initial in vitro experiments support using CS-based strategies
to re-sensitize resistant strains21 and reduce rates of resistance
development29; however, the broader application of this prin-
ciple depends on predictable bacterial responses during anti-
microbial therapy. This predictability must be general for a
given drug class and should not vary across strains of the same
species. To date, most studies of CS and CR have focused on
describing collateral networks21–23 using resistant mutants
derived from single laboratory-adapted strains and limited
numbers of clinical isolates. Two studies on Pseudomonas
aeruginosa have investigated CS in collections of clinical
isolates30,31. However, these studies lack either baseline con-
trols30 or sufﬁcient genetic diversity among tested strains31. As
valuable as earlier work has been, the responses of single strains
(laboratory or clinical) may not be representative of CS and CR
responses in other strains.
To address this limitation, here we focus on understanding
collateral networks in clinical urinary tract isolates of Escherichia
coli with selected resistance to drugs widely used for the treatment
of urinary tract infections: ciproﬂoxacin, trimethoprim, nitro-
furantoin, and mecillinam. We investigate collateral networks to
16 antimicrobials from diverse drug classes in 10 genetically
diverse clinical strains (corresponding to 49 laboratory-generated
mutants) to assess the factors contributing to collateral responses
(both CS and CR). This approach allows us to identify variation
in the sign and magnitude of collateral responses and identify
mechanisms of CS and CR that are preserved in various genetic
backgrounds. Using multivariate statistical modeling, we show
that resistance mutations, particularly those affecting efﬂux
pumps, and the relative ﬁtness of resistant isolates are more
important determinants of collateral networks than genetic
background. Our results support the idea that collateral responses
may be predictable.
Results
Collateral responses vary between and across resistance groups.
We examined collateral responses to antimicrobial resistance in
a panel of 10 genetically diverse (Supplementary Fig. 1a–b)
E. coli strains isolated from urinary tract infections. For each of
these pan-susceptible strains (Supplementary Fig. 1c)32, a single
resistant mutant was generated to each of four individual
antimicrobials used to treat urinary tract infections: cipro-
ﬂoxacin, trimethoprim, nitrofurantoin, and mecillinam. Here
we deﬁne resistance group as the collection of mutants from the
10 different genetic backgrounds that were selected for resis-
tance to the same antimicrobial. Mutants resistant to mecilli-
nam required only a single selection step, while multiple
selection steps were required to select for resistance above
clinical breakpoints for the remaining antimicrobials. In total,
40 resistant mutants were generated with resistance levels above
clinical breakpoints, as determined by antimicrobial suscept-
ibility testing using both gradient strip diffusion (Supplemen-
tary Table 1) and inhibitory concentration 90% (IC90)21 testing
(Table 1). The two methods are correlated, but IC90 measure-
ments allow for more robust detection of small relative differ-
ences in susceptibility33,34. Changes in the IC90 of resistant
mutants from each respective wild-type strain (Supplementary
Fig. 2) were compared for 16 antimicrobials (Table 2). Overall,
collateral responses were observed in 39% (233/590) of possible
instances (Supplementary Table 2); of these 49% (115/233)
were associated with only a 1.5-fold change in IC90. Such small
changes would not be observed by typical two-fold anti-
microbial susceptibility testing methods frequently used in
clinical laboratories.
Overall CR was more frequent than CS, 141 versus 92 instances
(Supplementary Table 2), and collateral networks varied con-
siderably between resistance groups. We observed 19 cases of
conserved collateral responses (Fig. 1a), where CR or CS to a
speciﬁc antimicrobial was found in ≥50% of the mutants within a
resistance group, deﬁned as CR50 or CS50, respectively. For each
CR50 and CS50 observation, IC90 results were further assessed by
generating dose–response curves of representative strain:drug
combinations (Supplementary Fig. 3). Inhibition of growth was
shown to vary across antimicrobial concentrations between
resistant mutants and respective wild-type strains, conﬁrming
the changes in antimicrobial susceptibility determined by the IC90
assays.
During the selection of resistant mutants, we often observed
colonies of varying size for all resistance groups, suggesting
changes to bacterial ﬁtness. To test this, we measured the growth
rates of mutants relative to the respective wild-type strains
(Supplementary Fig. 4). In general, mutants resistant to
ciproﬂoxacin and mecillinam displayed severely reduced growth
rates, suggesting high costs of resistance. Relative growth rates
varied between 0.34–0.75 with a mean of 0.53 for ciproﬂoxacin-
resistant mutants and between 0.49–0.79 with a mean of 0.64 for
mecillinam-resistant mutants. Mutants resistant to nitrofurantoin
and trimethoprim displayed lower ﬁtness effects, and several
resistant mutants harbored apparent cost-free resistance muta-
tions (Supplementary Fig. 4). Only two of ten nitrofurantoin-
resistant mutants and four of ten trimethoprim-resistant mutants
displayed an apparent cost of resistance. Relative growth rates
varied between 0.93–1.05 and 0.68–1.07 with averages of
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0.99–0.94 for nitrofurantoin- resistant and trimethoprim-
resistant mutants, respectively.
Ciproﬂoxacin resistance linked to conserved collateral
responses. Nearly half (108/233, 46%) of the observed collateral
responses were in ciproﬂoxacin-resistant mutants, while the
remaining 125 were distributed between the other three resistance
groups (Supplementary Table 2). Within the ciproﬂoxacin-
resistant group, the majority of collateral responses were CR
(70/108, 65%). Additionally, CS responses in ciproﬂoxacin-
resistant mutants were the most conserved in our dataset, with
CS to gentamicin occurring in 8 of 10 strains and CS to fosfo-
mycin in 7 of 10 strains (Fig. 1a). Gentamicin and other ami-
noglycosides are important for the treatment of a wide range of
infections35, while fosfomycin is primarily used for treatment of
uncomplicated urinary tract infections36,37. The ciproﬂoxacin-
resistant mutants were also unique in the magnitude of observed
changes, with cases of CR close to 30-fold and CS as high as six-
fold changes in IC90 (Supplementary Fig. 2).
Characterization of antimicrobial-resistant mutants. We
hypothesized that CS and CR variation in and between resistance
groups could be attributed to different mutations causing resis-
tance in each strain. Using whole genome sequencing, we iden-
tiﬁed a total of 149 mutations in the resistant mutants
(Supplementary Data 1–4). Of these, 88 mutations affect pre-
viously described or putative antimicrobial resistance-associated
genes, gene-regions, or pathways (Supplementary Data 1–4). The
remaining mutations were found in other cellular processes not
known to affect antimicrobial susceptibility (e.g. metabolic
pathways and virulence factors), such as mutation to the FimE
regulator of FimA that was frequently observed in mecillinam-
resistant mutants (Supplementary Data 2). Aside from FimE, we
did not observe mutations in regions unrelated to resistance
Table 1 Description of Escherichia coli strains used in the study and average IC90 changes following antimicrobial selection
Strain STa Origin CIPb MECb NITb TMPb
WTc cCIPR WTc cMECR WTc cNITR WTc cTMPR
K56-2 73 Greece 0.014 16 0.146 >30 8 >64 0.225 >28
K56-12 104 Portugal 0.016 1.67 0.273 28 7.33 >64 0.563 >32
K56-16d 127 Portugal 0.009 3 0.167 18.7 4 >64 0.25 >30
K56-41 73 Greece 0.016 2.33 0.104 13.3 6 >64 0.25 6.67
K56-44d 12 Greece 0.013 1.67 0.141 16 6.67 >64 0.375 6
K56-50 100 Greece 0.012 3 0.141 10.7 12 >64 0.172 18
K56-68 95 Sweden 0.014 4 0.141 30 6.67 >64 0.208 18.7
K56-70 537 Sweden 0.007 2.67 0.083 >32 4.67 >64 0.25 14.7
K56-75e 69 UK 0.008 1.17 0.063 13 6 >64 0.167 5.33
K56-78 1235 UK 0.015 6 0.141 16 8 >64 0.5 7.33
aMulti-locus sequence type (ST)
bThe average IC90 values (µgmL−1) of three or more biological replicates for wild type (WT) and resistant (R) mutants to ciproﬂoxacin (CIP), mecillinam (MEC), nitrofurantoin (NIT), and trimethoprim
(TMP). Individual results above detection limits (MEC= 32 µgmL−1, NIT= 64 µgmL−1, TMP= 32 µgmL−1) were analyzed as those values, yielding ﬁnal results with uncertainty (>average). EUCAST
Clinical Breakpoints v 7.1 for Enterobacteriaceae63 were: >0.5 µg mL−1 CIP, >8 µgmL−1 MEC, >64 µgmL−1 NIT, and >4 µg mL−1 TMP
cThe strain number names the WT, and designations CIPR, MECR, NITR, and TMPR describe which drug the isolates were selected with, and resistance achieved
d, eStrains containing the Col156 or Col(MP18) replicon, respectively
Table 2 List of antimicrobials used in this study
Antimicrobiala Abbreviation Drug class Drug target(s) Solvent
Amoxicillin AMX β-lactam (Penicillin) Cell wall synthesis Phosphate bufferb
Azithromycin AZT Macrolide Protein synthesis (50S) ≥95% Ethanol
Ceftazidime CAZ β-lactam (Cephalosporin) Cell wall synthesis Water+ 10% (ww-1) Na2CO3
Chloramphenicol CHL Amphenicol Protein synthesis (50S) ≥95% Ethanol
Ciproﬂoxacin CIP Fluoroquinolone DNA replication, cell division 0.1 N HCl
Colistin COL Polymyxin Cell wall & cell membrane Water
Ertapenem ETP β-lactam (Carbapenem) Cell wall synthesis Water
Fosfomycin FOS Phosphonic Cell wall synthesis (MurA) Water
Gentamicin GEN Aminoglycoside Protein synthesis (30S) Water
Mecillinam MEC β-lactam (Penicillin) Cell wall synthesis (PBP2) Water
Nitrofurantoin NIT Nitrofuran Multiplec Dimethyl sulfoxide
Trimethoprim TMP Antifolate Folate synthesis (FolA) Dimethyl sulfoxide
Sulfamethoxazole SMX Antifolate Folate synthesis (FolP) Dimethyl sulfoxide
TMP+ SMX (1:19) SXT Antifolate Folate synthesis (FolA+ FolP) Dimethyl sulfoxide
Temocillin TEM β-lactam (Penicillin) Cell wall synthesis Water
Tetracycline TET Tetracycline Protein synthesis (30S) Water
Tigecycline TGC Tetracycline Protein synthesis (30S) Water
aWhen available, ﬁnal antimicrobial concentration was determined using manufacturer-provided or calculated drug potencies, otherwise potency was assumed to be 100%. Aliquots were stored at −20
or −80 °C in single-use vials. All antimicrobials and chemical solvents were obtained from Sigma-Aldrich (St. Louis, MO, USA) with the exception of ciproﬂoxacin (Biochemika, now Sigma-Aldrich) and
temocillin (Negaban®)
b0.1 mol L−1, pH 6.0 phosphate buffer supplemented with 6.5% (v v−1) 1 M NaOH (sodium hydroxide)
cNitrofurantoin is thought to target macromolecules including DNA and ribosomal proteins, affecting multiple cellular processes, including protein, DNA, RNA, and cell wall synthesis
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across mutants of the same resistance group (parallel evolution),
suggesting that such mutations had limited, if any, effect on
collateral responses in this study.
For each of the 40 resistant mutants at least one putative
resistance mechanism was identiﬁed, including mutations to
previously described antimicrobial drug targets and promoters of
drug targets, drug-modifying (activating) enzymes, regulators of
efﬂux pumps, RNA polymerases and mutations to other
metabolic and biochemical processes that may contribute to
resistance (Table 3). Brieﬂy, all but one ciproﬂoxacin-resistant
mutant contained mutations in both gyrA and efﬂux regulatory
genes and/or gene-regions likely affecting efﬂux expression
(acrAB and/or mdtK), while one strain had only drug target
mutations and displayed the well-described GyrA (S83L) and
ParC (G78D) mutation combination (Supplementary Data 1).
Both efﬂux and drug target mutations are frequently found in
surveys of clinical isolates38–41. Nitrofurantoin-resistant mutants
had mutations in one or both nitro-reductases (nfsA, nfsB) and
the majority of strains had additional mutations in mprA, which
encodes an efﬂux regulator of EmrAB-TolC pump expression
(Supplementary Data 3). Mutants resistant to trimethoprim
contained mutations either in folA and/or its promoter or genetic
ampliﬁcation of a large region containing folA (Supplementary
Data 4). The mecillinam-resistant mutants are unique in that they
evolved as single step mutants, where a single mutation could
confer clinical resistance to mecillinam. Resistance development
for the remaining three drugs required several steps, as multiple
mutations were required for resistance above clinical breakpoints.
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Fig. 1 Conserved collateral responses in antimicrobial resistant mutants. a Relative change in antimicrobial susceptibility was determined by comparing
average IC90 values of resistant mutants to the respective wild-type strain. Collateral responses that were found in ≥50% of the strains are displayed,
excluding CR observed in all trimethoprim-resistant mutants to trimethoprim-sulfamethoxazole (see Supplementary Fig. 2). Antimicrobials are ordered by
most frequent CR (red; left) to most frequent CS (blue; right) for each group. *The slow growing K56-12 CIPR was incubated an additional 24 h for IC90
determination. b The average IC90 (open circles) and average mutation prevention concentration (MPC; ﬁlled circles) were determined and compared
between resistant mutants (colored) with collateral responses, either CS (blue) or CR (red), and their respective wild-type strain (black) in strain:drug
combinations representing conserved collateral responses, excluding temocillin. The mutant selection window (vertical lines) was deﬁned as the range
between IC90 (lower bound) and MPC (upper bound). K56-16 NITR had equivalent IC90 and MPC values for azithromycin, thus no mutation selection
window was reported. Generally, changes in MPC values reﬂected observed IC90 changes, shifting the mutation selection window upwards or downwards
accordingly. In 8/10 tested combinations an increase in IC90 value (CR) from wild-type to resistant mutant correlated with at least a small increased MPC,
with the remaining combinations showing no change in MPC value. Similarly, decreased IC90 values (CS) correlated with decreased MPCs (5/7)
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In total, 12 different mutations in genes and/or cellular processes
previously linked to mecillinam resistance were identiﬁed in this
resistance group (Supplementary Data 2)42.
The ciproﬂoxacin-resistant group displayed a clear trend where
conserved CR responses were strongly linked to mutations in
efﬂux regulatory regions suggesting that gyrA drug target
mutations had a limited effect on CS and CR. Trimethoprim-
resistant mutants also had few collateral responses, likely due to
the speciﬁc mechanism of resistance affecting a single unique
drug target (i.e. overexpression/alteration of FolA). To further
investigate the effects of drug target mutations, we assessed the
collateral responses of mutants generated following a single
selection-step with ciproﬂoxacin. These ﬁrst-step mutants con-
tained single, non-synonymous mutations to gyrA and no other
mutations (e.g. in efﬂux pumps) linked to ciproﬂoxacin resistance
(Supplementary Data 1). The IC90 of these strains was uniformly
lower than in ciproﬂoxacin-resistant strains containing multiple
resistance mutations. Few collateral responses were observed in
these ﬁrst-step mutants (Fig. 2), and none were conserved across
different strain backgrounds. These results suggest that most
collateral responses observed in the ciproﬂoxacin-resistant
mutants are due to the observed efﬂux mutations.
Efﬂux and ﬁtness are main contributors to collateral responses.
Multivariate statistical approaches were used to investigate the
extent to which genetic (strain) background, resistance group, the
putative mechanism of resistance (in particular efﬂux-related
mutations), growth rate, and the ﬁtness cost of resistance explain
the variation in collateral responses. All factors were investigated
individually (Supplementary Fig. 5a–e). Throughout the
remaining analyses we focus mainly on efﬂux-related mutations,
rather than resistance group, to explicitly address putative
mechanisms of resistance, and relative ﬁtness rather than growth
rate.
We estimated several models with individual, or a combination
of, factors to assess their effect size and signiﬁcance given some
level of collinearity between ﬁtness and efﬂux-type (Fig. 3,
Supplementary Fig. 5a–r). A model including strain background,
relative ﬁtness, and efﬂux-related mutations as factors explained
62.5% of the total variation in IC90 values (Fig. 3a, b,
Supplementary Table 3). In this three-factor model there was
clear separation of the mutants by resistance group (Fig. 3a). The
ciproﬂoxacin-resistant mutants showed strong CR towards
temocillin, chloramphenicol, ceftazidime, and amoxicillin, separ-
ating this resistance group from the others along the ﬁrst
ordination axis (Fig. 3a, b). Along the second ordination axis,
mecillinam-resistant isolates were distinct, had CR to temocillin,
and were more likely to have CS towards drugs, such as
azithromycin and chloramphenicol (Fig. 3a, b). Both efﬂux-type
and relative ﬁtness were signiﬁcant predictors when tested alone
and in combination (Supplementary Table 3). The model (Fig. 3a,
b) also revealed that strain background had a non-signiﬁcant
(p= 0.993) contribution (Supplementary Table 3). Even when
modeled alone (Supplementary Fig. 5a), strain background only
accounted for 6.5% of the variation and was non-signiﬁcant
(Supplementary Table 3).
We initially hypothesized that genetic background would
signiﬁcantly affect collateral responses. Our initial analysis
suggests that it does not. Arguably, the inclusion of IC90 data
from the drugs to which primary resistance was selected could
confound the analysis, despite our efforts to minimize these
effects using log-transformed data. We used the same approaches
to assess a subset of collateral responses, excluding data for all of
the 40 resistant mutants to ﬁve antimicrobials containing the
drugs used for selection (ciproﬂoxacin, mecillinam, nitrofuran-
toin, trimethoprim) and trimethoprim-sulfamethoxazole. Within
the subset model, patterns consistent with the full model were
observed, but with a lower degree of clustering by resistance
group (Fig. 3c). For example, K56-2 CIPR is now co-localized
with the mecillinam-resistant isolates, indicating that this isolate
is distinct from other ciproﬂoxacin-resistant mutants (Fig. 3c),
which still showed strong tendencies of CR to temocillin,
chloramphenicol, ceftazidime, and amoxicillin (Fig. 3c, d).
Despite these changes, efﬂux-type and ﬁtness were still signiﬁcant
predictors of collateral networks, and strain background
remained non-signiﬁcant (Supplementary Table 3) when mod-
eled alone (Supplementary Fig. 5f) and in two-factor combina-
tions (Supplementary Fig. 5n–o), but had a limited, signiﬁcant
contribution (p= 0.040), determined by permutation tests, in the
three-factor model (Fig. 3c, d, Supplementary Table 3). However,
mutations in efﬂux-related genes and gene regulators were the
strongest predictor of collateral responses tested, explaining over
33% of the variation in the subset. Fitness alone also had
signiﬁcant predictive value, but to a lesser extent (17% variation
explained). It is important to note that we observed a correlation
between efﬂux mutations and relative ﬁtness that is likely
explained by reduced ﬁtness resulting from the cost of over-
expression of efﬂux pump(s)39.
To investigate the inﬂuence of resistance mechanism on IC90
variation at a higher resolution, we modeled each resistance
group separately relating the putative resistance mechanism
(beyond efﬂux-type) and ﬁtness separately and in combination
(Supplementary Fig. 6a–o). However, potentially due to a lower
number of samples within each resistance group that were
separated into more detailed classiﬁcations of resistance mechan-
ism, these factors had varying degrees of contribution. For
mutants resistant to ciproﬂoxacin (Supplementary Fig. 6a) and
trimethoprim (Supplementary Fig. 6j), resistance mechanism was
non-signiﬁcant, but it was a signiﬁcant factor for those resistant
to mecillinam (Supplementary Fig. 6d) and nitrofurantoin
(Supplementary Fig. 6g). Fitness was a signiﬁcant factor only
for the mecillinam resistance group (Supplementary Fig. 6e) and
similarly, models containing both resistance mechanism and
ﬁtness were non-signiﬁcant for all resistance groups, with the
exception of the mecillinam-resistant mutants (Supplementary
Fig. 6f).
In the ﬁrst-step (GyrA) ciproﬂoxacin mutants, strain back-
ground was a signiﬁcant factor for collateral responses
Table 3 The number of antimicrobial resistant mutants with
resistance-associated mutations
Resistance
mechanism
CIPR MECR NITR TMPR
Drug target Modiﬁcation 10a 6
Overproduction 6
Drug activation Nitroreductase
disruption
10
Drug uptake Porin mutation 1
Efﬂux AcrAB-TolC 7 1
MdtK 9 1
MdfA 1
EmrAB-TolC 7
ABC transport 1
ppGpp
synthesis
(stringent
response
activation)
Stringent
response
4
tRNA synthesis 4
tRNA processing 1
Cellular
metabolism
3
aAll mutants resistant to ciproﬂoxacin contained one mutation in the gyrA gene, except the K56-
2 CIPR mutant that contained two mutations in gyrA and a mutation in parC
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Fig. 2 Collateral effects in gyrA mutants with decreased susceptibility to ciproﬂoxacin. Relative changes in antimicrobial susceptibilities, CS (blue) and CR
(red), were determined by comparing average IC90 values of nine ﬁrst-step mutants to their respective wild-type strain. Antimicrobials are ordered by
antimicrobial class, as in Supplementary Fig. 2
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Fig. 3 Results of multivariate statistical modeling. Graphical representations of two redundancy analyses (RDA, triplot) results relating various parameters
to the observed changes in IC90 between resistant mutants and respective wild-type strains for (a, b) 16 antimicrobials tested and (c, d) a subset of these
antimicrobials, excluding ciproﬂoxacin, mecillinam, nitrofurantoin, trimethoprim, and trimethoprim-sulfamethoxazole. Each RDA is broken down into two
plots; (a, c) where weighted averages of resistant mutants are plotted as colored symbols (color indicates resistance group, shape the assigned efﬂux
group, and symbol size proportional to relative ﬁtness, see Supplementary Fig. 4). In (b, d) antimicrobial drug names indicate the tip of vectors that pass
through the origin in the direction of increasing IC90 fold change or CR (direction of steepest ascent). Vectors can be used to interpret the change in IC90
for the antimicrobials shown. For both statistical models, the ﬁrst and second RDA axes shown display the majority of explained variation in IC90 changes.
Large gray symbols show centroids (average effect) for all resistant mutants within a given efﬂux group (shape). The vector tip of relative ﬁtness (brown)
is also shown. a The majority of explained variation is driven by primary resistances, where ciproﬂoxacin (pink)-resistant and mecillinam (green)-resistant
mutants cluster distinctly from the other resistance groups, which showed higher relative ﬁtness. b Resistant mutants possessing MdtK mutations alone
(diamond) or together with AcrAB-TolC mutations (circle) are likely to show CR to chloramphenicol, ceftazidime, temocillin, and azithromycin, but
sensitivity to gentamicin, fosfomycin, and trimethoprim. Whereas those without efﬂux mutations (triangle) are more likely to display low-level CS or no
change to most antimicrobials tested. The analysis of the subset RDA (c, d) shows patterns consistent with the full model, but with less clustering of
mutants by resistance group (c). The combination of AcrAB-TolC and MdtK efﬂux mutations displayed the greatest ﬁtness costs, while mutants lacking
efﬂux-related mutations were the most ﬁt (d). RDA signiﬁcance was assessed by permutation tests (1000 permutations), where p≤ 0.05 was considered
signiﬁcant. For more comprehensive multivariate models see Supplementary Fig. 5–6
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(Supplementary Fig. 6m). However, this was not the case when
the original ciproﬂoxacin-resistant mutants from the same strain
backgrounds were added to the analysis (Supplementary Fig. 6n),
suggesting again that other factors are more important than strain
background. Overall, in comparison to the ciproﬂoxacin-resistant
mutants, collateral responses of ﬁrst-step mutants were far less
frequent and more closely resembled those of the GyrA/ParC
mutation-containing K56-2 CIPR mutant. A ﬁnal redundancy
analysis was performed on all ciproﬂoxacin-resistant and ﬁrst-
step mutants (Supplementary Fig. 6o), and showed a signiﬁcant
effect of resistance mechanism, supporting that mechanism,
efﬂux in particular, is a major driver of collateral responses.
Collateral responses shift the mutation selection window. The
mutant selection window can be deﬁned as the concentration
space between the lowest antimicrobial concentration that selects
for and enriches resistant mutants43 and the concentration that
prevents the emergence of ﬁrst-step resistant mutants, the
mutation prevention concentration (MPC)44,45. In theory, if drug
concentrations remain above the MPC during treatment, anti-
microbial resistance is less likely to evolve44,45. It was recently
demonstrated in E. coli MG1655 that changes in MPC correlated
with collateral responses in resistant mutants21. We determined
the MPC for 17 strain:drug combinations that exempliﬁed con-
served collateral responses (Fig. 1b). The MPC for each resistant
mutant and its respective wild-type were compared. In 12/17
(70.6%) the change in MPC was consistent with the sign of col-
lateral responses as determined by IC90. This demonstrates that
even small CS/CR changes can affect the mutant selection win-
dow, correspondingly shifting it down or up. In 4/17 (23.5%) the
MPC displayed no change between the wild-type and mutant.
This was observed when testing the MPC for mecillinam, tri-
methoprim, and azithromycin, though we speculate that
increasing the precision of the MPC assay (as was done with IC90
testing) might negate these discrepancies. Changes in MPC
results with azithromycin were inconsistent with the change in
IC90 for a ciproﬂoxacin-resistant mutant and the mutants resis-
tant to mecillinam and nitrofurantoin, which displayed a
decreased MPC instead of an expected increase or no change,
respectively.
Discussion
Here, we identify conserved collateral responses in antimicrobial
susceptibility across genetically diverse clinical E. coli strains
following antimicrobial resistance development. Our ﬁndings are
relevant beyond urinary-tract infections because uropathogenic
E. coli are shown to also stably colonize the bladder and gut46 and
to cause bloodstream infections47. Our data show that CS and CR
are pervasive in clinical E. coli strains, consistent with earlier
results based on laboratory-adapted strains of various species21–
23,25,30,48 and a limited number of clinical isolates21,30. Resistance
to ciproﬂoxacin resulted in a greater number of collateral
responses than resistance to mecillinam, nitrofurantoin, or tri-
methoprim. This is likely due to mutations to known regulators of
the AcrAB-TolC and MdtK efﬂux pumps. Both have broad
substrate speciﬁcities to diverse antimicrobials including ﬂuor-
oquinolones, β-lactams, tetracycline, chloramphenicol, trimetho-
prim-sulfamethoxazole, and some macrolides for the AcrAB-
TolC efﬂux pump49,50, and ﬂuoroquinolones, chloramphenicol,
trimethoprim, and some β-lactams for the MdtK pump39,51.
Interestingly, both overexpression of MdtK51 and RpoB39 muta-
tions (that were linked to MdtK expression) have been shown to
reduce susceptibility to fosfomycin, as was observed in the
ciproﬂoxacin-resistant mutants in this study (Fig. 1a). Overall, CR
was much more prevalent than CS, and the magnitude of
collateral responses were most often small, consistent with other
reports21–23. We observed that collateral responses varied sub-
stantially by resistance group, but variation was also observed
within resistance groups.
Using CS50 and CR50 thresholds to identify conserved
responses, we found that conserved CR was more than twice as
common as conserved CS. Whereas many of the conserved col-
lateral responses identiﬁed in this study support the ﬁndings in
previous work using single laboratory-adapted strains, we
observed several clinically relevant differences. For example, our
ﬁnding of conserved CS in ciproﬂoxacin-resistant mutants to
gentamicin was previously reported in E. coli K1222 but not in E.
coli MG165521. In mutants resistant to ciproﬂoxacin we also
observed conserved CR towards chloramphenicol, as reported in
ref. 21, but not in ref. 23. We identiﬁed conserved CR of
nitrofurantoin-resistant mutants to amoxicillin, and this was not
reported in MG165521. These observations underscore the
importance of exploring collateral networks in multiple mutants
of different clinical strain backgrounds and with different resis-
tance mechanisms to assess their potential clinical application.
Visual inspection of the data revealed a few clinically relevant
examples of CS phenotypes that appeared independent of puta-
tive mechanism of resistance. We show that E. coli strains resis-
tant to ciproﬂoxacin display CS towards gentamicin, fosfomycin,
ertapenem, and colistin, and these phenotypes were conserved
across multiple mechanisms of resistance. These results parallel
those of a recent study on P. aeruginosa clinical isolates from
cystic ﬁbrosis patients, where resistance to ciproﬂoxacin was
associated with CS to gentamicin, fosfomycin, and colistin31.
Taken together these data support the presence of general, con-
served collateral networks that may both affect the population
dynamics of antimicrobial resistance during treatment and
counter-select for resistance, as recently indicated31.
We assumed a priori that genetic background, resistance
group, resistance mechanism, and the ﬁtness cost of resistance
could potentially affect the generality, sign, and magnitude of
collateral networks in clinical E. coli strains. Despite the fact
that some collateral responses are conserved across different
strains and mechanisms of resistance, our multivariate statis-
tical approaches show overall that mechanism of resistance is
the key predictor of CS and CR variability. This is primarily the
case for efﬂux-related mutations. However, mechanism of
resistance also signiﬁcantly contributed to the observed CS and
CR variation in the mecillinam mutants where no efﬂux
mutations were found. The presented data are consistent with
earlier reports based on multiple resistant mutants derived from
single strains with different resistance mechanisms towards
speciﬁc antimicrobials22,23,52. Our ﬁnding that genetic back-
ground did not signiﬁcantly contribute to collateral responses is
an important addition to these earlier studies. Finally, we found
that the ﬁtness cost of resistance also contributed signiﬁcantly
to the observed variation in CS and CR, despite some colli-
nearity between efﬂux-related mutations and reduced ﬁtness.
Taken together, our data and previous reports indicate that
applied use of collateral networks in future treatment strategies
may be dependent on rapid identiﬁcation of speciﬁc resistance
mechanisms. Moreover, clinical application of CS as a selection
inversion strategy warrants further investigations to ideally
explore CS in isogenic backgrounds, representing several
diverse strains, with permutations of all known antimicrobial
resistance-associated traits. Such extensive studies would likely
provide valuable information on the mechanisms of CS. Other
confounding factors such as mobile genetic elements with
heterogeneous resistance determinants should also be investi-
gated as they would likely inﬂuence and reduce the predict-
ability of collateral networks.
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Selection inversion, as described by ref. 21, depends on the
cycling of drug pairs that display reciprocal CS. We did not
observe reciprocal CS between any of the four drugs studied here
that are widely used for treatment of urinary tract infections.
However, we asked if modest reductions and increases in anti-
microbial susceptibilities would affect the mutant selection win-
dow44 for the most prevalent CS and CR phenotypes. We
subjected conserved CS and CR phenotypes to MPC assays and
revealed that even a small 1.5-fold change in IC90 could equally
alter the MPC, resulting in a shift of the mutant selection win-
dow (Fig. 1b). These results suggest that antimicrobial treatment
strategies informed by collateral networks could affect the evo-
lutionary trajectories of antimicrobial resistance. Sequential
treatment using drug pairs that display CR would, following
resistance development, shift the mutant selection window
towards higher antimicrobial concentrations, as was previously
observed53, and increase the likelihood for resistance develop-
ment to subsequent treatment options (Fig. 4a). Conversely,
sequential treatment based on drug pairs that display CS can shift
the mutant selection window down and reduce the window of
opportunity for high-level resistance development (Fig. 4b). This
result suggests that the initial choice of antimicrobial may set the
stage for later resistance development.
Based on our in vitro ﬁndings, trimethoprim and nitrofur-
antoin are attractive from a clinical perspective, as resistance to
these resulted in few collateral responses, preserving the innate
sensitivity to available secondary antimicrobials (Fig. 4c, d).
However, mecillinam could be even more attractive, as CS
largely dominates the observed collateral responses in resistant
mutants. Additionally, isolates resistant to mecillinam,
especially those evolved in vivo, are associated with high ﬁtness
costs42. In contrast, exposure to ciproﬂoxacin was more likely
to cause dramatic collateral responses that depend on the
mechanism of resistance and could potentially negatively
impact future therapeutic options (Fig. 4c). These observations
align with antimicrobial treatment recommendations in Nor-
way, where mecillinam, nitrofurantoin, and trimethoprim are
recommended for ﬁrst-line therapy of uncomplicated urinary-
tract infections, and ciproﬂoxacin is reserved for otherwise
complicated infections54. Similarly, in the United States nitro-
furantoin, trimethoprim-sulfamethoxazole, and mecillinam are
recommended before ﬂuoroquinolones, such as ciproﬂoxacin,
oﬂoxacin, and levoﬂoxacin55.
Our conclusions are not without limitations. First, we
acknowledge that including more clinical isolates from different
infection foci, more diverse genetic backgrounds including dif-
ferent bacterial species, as well as other selective agents, could
change the outcome of our statistical analyses. This would allow
increased sensitivity for the assessment of the different factors
controlling collateral responses. A more targeted approach to
assess the impact of speciﬁc resistance mechanisms on CS and CR
across genetically diverse clinical strains is lacking in the ﬁeld.
Our analyses suggest that the ﬁtness cost of resistance explains
some variability in the collateral networks reported here. We used
relative growth rates as a proxy for relative ﬁtness, and our data
are consistent with reports demonstrating that growth rates affect
susceptibilities to several antimicrobials56,57. It is unclear if col-
lateral networks will be perturbed by compensatory evolution,
which eliminates the ﬁtness costs of primary resistance58–60.
Finally, this and previous studies focus on antimicrobial
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resistance development to a single drug, and there is a complete
lack of data on how multidrug resistance, including resistance
genes on mobile genetic elements, will affect collateral networks.
We are currently investigating these and other questions that will
aid in our understanding of collateral networks and their
potential therapeutic application.
Methods
Bacterial strains. We used 10 clinical, urinary-tract infection isolates of E. coli
from the ECO-SENS collections61,62 originating from countries across Europe
between 2000 and 2008 (Table 1). The isolates were chosen to represent pan-
susceptible strains with diverse genetic backgrounds and were reported plasmid-
free32. Subsequent analysis based on whole-genome sequencing discovered two
changes to previously reported sequence types and the presence of plasmid repli-
cons in three strains (Supplementary Table 4). E. coli ATCC 25922 was used for
reference and quality control purposes. For general growth, bacterial strains were
grown in either Miller Difco Luria–Bertani (LB) broth (Becton, Dickinson and Co.,
Sparks, MD, USA) or on LB agar; LB broth with select agar (Sigma-Aldrich) at 15 g
L−1 and incubated at 37 °C.
Selection of antimicrobial-resistant mutants. Single antimicrobial-resistant
mutants were selected at drug concentrations above the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints63 for cipro-
ﬂoxacin, nitrofurantoin, trimethoprim, and mecillinam (Supplementary Table 1).
Brieﬂy, 100 µL of 10× concentrated overnight culture was spread on Mueller
Hinton II agar (MHA-SA; Sigma-Aldrich) plates containing ciproﬂoxacin (Bio-
chemika), nitrofurantoin (Sigma-Aldrich), or trimethoprim (Sigma-Aldrich) with
two-fold increasing concentrations of the antimicrobial. After 24–48 h, a mixture of
growth from the highest concentration plate with multiple colonies was used to
start a new overnight culture at the same antimicrobial concentration. This was
repeated until there was growth above the clinical breakpoint63. Mecillinam-
resistant mutants and ﬁrst-step ciproﬂoxacin mutants (gyrA mutation-containing)
were selected as single-step mutants on LB or MHA-SA agar, respectively. Mutants
were conﬁrmed as E. coli using matrix-assisted laser desorption ionization time-of-
ﬂight (MALDI-TOF) analysis with MALDI BioTyper software (Bruker, MA, USA).
Antimicrobial susceptibility testing. Mutants were initially screened for resis-
tance above EUCAST breakpoints63 with gradient diffusion strips following
manufacturers guidelines (Lioﬁlchem, Italy), on Mueller Hinton II agar (MHA-BD;
Becton, Dickinson and Company). Plates with insufﬁcient growth were incubated
for an additional 24 h.
To maximize the precision of our susceptibility estimates and in accord with
related studies on CS, collateral changes were determined by IC90 testing21 with
some modiﬁcations. IC90 values were determined following 18 h incubation at 700
rpm (3 mm stroke) in Mueller Hinton Broth (MHB, Becton, Dickinson and Co.).
Slow-growing strains where positive growth controls did not reach OD600 nm of 0.3
after 18 h (i.e. K56-12 CIPR) were interpreted after 42 h incubation. Standard two-
fold concentrations and the median values between them were used as a 1.5-fold
testing scale. IC90 values were the lowest concentration tested that resulted in ≥90%
inhibition of growth. Percent inhibition was calculated compared to the positive
control (untreated sample) with background removed21. IC90 results were
determined in at least three biological replicates on separate days. The ﬁnal result
reﬂects the average of a minimum of three replicates that met quality control
standards, including the result of ATCC 25922 on each plate, positive growth
control OD600 nm > 0.3, negative growth control OD600 nm < 0.05, and accepting no
more than one skip (deﬁned as a break in the inhibition pattern). When one skip
was observed, the IC90 value was consistently interpreted as the lowest
concentration tested that resulted in ≥90% inhibition of growth. Fold change in
IC90 was calculated as the ratio between the resistant mutant and its respective
wild-type. The IC90 testing varied for two antimicrobials (according to EUCAST
recommendations), where fosfomycin was tested in MHB supplemented with
25 µg mL−1 glucose-6-phosphate (Sigma-Aldrich) and tigecycline was tested in
fresh MHB media that was prepared daily.
Dose–response curves were generated with average OD600 values (background
subtracted) for concentrations tested during IC90 testing. Averages were plotted for
mutants and respective wild-type strains.
MPC testing. We determined the MPC for 17 of 20 conserved collateral responses.
Temocillin was excluded due to lack of supply and trimethoprim-sulfamethoxazole
was excluded for trimethoprim-resistant isolates due to fundamental CR between
trimethoprim and trimethoprim-sulfamethoxazole. MPC determination was based
on previous work by Marcusson et al.64. Brieﬂy, 10 mL overnight culture was
centrifuged and the pellet re-suspended in 1 mL MHB, estimated to contain ≥1010
CFU (actual values were 1.4 × 1010–7 × 1010 CFU). The inoculum was split and
spread onto four large (14 cm diameter) MHA-SA agar plates for each anti-
microbial concentration tested in a two-fold dilution series. The MPC was the
lowest concentration with no visible growth after 48 h. Where growth/no growth
was difﬁcult to interpret, suspected growth was re-streaked on plates at the same
antimicrobial concentration. Azithromycin and ertapenem were regularly incon-
sistent, making re-streaking essential. Resistant mutants and wild-types were tested
in parallel, and results represent the average of at least two biological replicates.
Growth rate measurements. To obtain growth curves of wild-types and resistant
mutants, single colonies were used to inoculate at least three biological replicates of
MHB starter cultures (2 mL) that were incubated at 37 °C for 24 h shaking at 500
rpm. Each culture was diluted 1:100 in MHB (resulting in ~2 × 107 cell mL−1) and
250 µL was added in triplicate to a 96-well microtiter plate. The plate was incubated
overnight at 37 °C in a Versamax plate reader (Molecular Devices Corporation,
California, USA) with shaking for 9.2 min between reads. OD600 measurements
were taken every 10 min and growth rates were estimated using the GrowthRates
v.2.1 software65. To a varying extent, the ciproﬂoxacin-resistant mutants of K56-12,
K56-16, K56-44, and K56-68, as well as, K56-44 MECR, K56-68 MECR, and K56-70
TMPR displayed noise in the growth curves due to clumping or non-homogeneous
growth, and GrowthRates was unable to ﬁt a line with R-value above the 0.98 cut-
off value. Additional experiments and visual inspection of the log-transformed
OD600 values were used to solve this issue. If GrowthRates failed to analyze the
curves, a line was ﬁtted within the log phase through at least ﬁve consecutive points
that displayed log-linear growth. Growth rate (r) was calculated based on the
slope65. Relative growth rates were calculated as r(resistant mutant) r(wild-type)−1.
Whole genome sequencing. Genomic DNA was isolated using the GenElute
Bacterial Genomic DNA kit (Sigma-Aldrich) following guidelines for Gram-
positive DNA extraction. Purity and quantiﬁcation was determined with Nanodrop
(Thermo Scientiﬁc) and Qubit High Sensitivity DNA assay (Life Technologies),
respectively. For library preparation of wild-types and resistant mutants, 1 µg of
DNA was sheared on a Covaris S2 to ≈400 bp using the recommended settings
(intensity: 4, duty cycle: 10%, cycles per burst: 200, treatment time: 55 s). Libraries
were then prepared and indexed using the DNA Ultra II Library Preparation Kit
(New England Biolabs, E7645). For library preparation of DNA from ﬁrst-step
ciproﬂoxacin mutants, 1 ng of DNA was used with the Nextera XT DNA prep kit
(Illumina, San Diego), according to the producer’s instructions. All libraries were
quantiﬁed by Qubit High Sensitivity DNA assay and distributions and quality
assessed by Bioanalyser DNA 1000 Chip (Agilent, 5067-1504) before normalizing
and pooling. Illumina sequencing, NextSeq 550, and MiSeq, was used for the ﬁrst-
step ciproﬂoxacin mutants and the wild-types and resistant mutants, respectively,
using paired-end reads. For NextSeq 550 a mid-output ﬂowcell with 300 cycles was
used. V2 chemistry was used for the MiSeq sequencing.
Wild-type genomes were assembled, as follows. Illumina adapters on wild-type
reads were removed with Trimmomatic version 0.3666 using standard settings, then
assembled with SPAdes67. Contigs less than 500 bp in length or less than 2.0
coverage were removed. Wild-type genome assemblies were inspected and
compared to the E. coli MG1655 genome (GenBank U00096.2) using QUAST68.
Final assembled genomes of wild-type strains were annotated using the automated
Prokaryotic Genome Annotation Pipeline (https://www.ncbi.nlm.nih.gov/genome/
annotation_prok/).
Wild-type and mutant sequences were compared to identify putative resistance
mechanisms. First, wild-type genomes were annotated with Rapid Annotation
using Subsystem Technology server (RAST, version 2.0) for E. coli69. SeqMan
NGen (DNASTAR, Madison, WI) was used to align raw mutant reads to the
corresponding, annotated wild-type genomes, using standard settings. Reported
SNPs had ≥10× coverage depth and ≥90% variant base calls. SNPs present in the
wild-type assembly or in at least two mutants resistant to different antimicrobials
from the same strain background were excluded. Reported SNPs, indels, and
rearrangements were manually inspected and gene annotations conﬁrmed using
Gene Construction Kit (Textco Biosoftware Inc., Raleigh, NC) and NCBI BLAST
searches, respectively.
Multilocus sequence typing (MLST), as well as, plasmid replicon and acquired
antimicrobial resistance gene content were determined for the wild-type genomes
using MLST version 1.8, PlasmidFinder version 1.3, and ResFinder version 3.070,
respectively (http://genomicepidemiology.org/). The MLST of each wild-type strain
was conﬁrmed compared to the original reported sequence type32 for all but two
strains, K56-41 and K56-70. These strains were originally described as ST420 and
ST550, but were ST73 and ST537 in our analysis, respectively (Supplementary
Table 4). The wild-type strains were previously described as plasmid free, but we
identiﬁed two small plasmid replicons, Col156 in K56-16 and K56-44 and Col
(MP18) in K56-75 (Supplementary Table 4). Using ResFinder, we detected only
one acquired genetic element, sul2 (linked to sulfonamide resistance) in K56-44,
and two point mutations, PmrB V161G in K56-50 and K56-70 and ParE D475E in
K56-78, that are linked to colistin and quinolone (ciproﬂoxacin) resistance,
respectively (Supplementary Table 4). Though all of the wild-type strains were
phenotypically pan-susceptible (Supplementary Fig. 1c), these resistance
determinants could affect antimicrobial susceptibilities differentially in the
presence of other mutations71,72.
To assess genetic diversity, a phylogenic tree was generated based on the
genome sequences of wild-type strains. Assembled wild-type genomes were
annotated with PROKKA73, the core gene-encoding regions were extracted and
compared using ROARY74, and a maximum-likelihood tree with 100 bootstraps
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was generated using RAxML75. Genetic distances were calculated in R76 using
previously described methods77.
Multivariate statistical analyses. The fold changes of mean IC90 values relative
to the parental wild-type strain (collateral responses) were log transformed.
Statistical analyses were performed on the complete data set, as well as a subset
of the data excluding ﬁve antimicrobials (ciproﬂoxacin, mecillinam, nitrofur-
antoin, trimethoprim, and trimethoprim-sulfamethoxazole). To estimate and
test the effects of strain background, resistance group, resistance mechanism,
growth rate, and relative ﬁtness we relied on multivariate modeling (redundancy
analysis) to address the co-variation in IC90 across antimicrobials. A redundancy
analysis is a constrained version of a principle component analysis that addi-
tionally allows for hypothesis testing. Linear constraint scores were plotted for
each mutant. Response variables were overlaid with independent scaling to
illustrate the direction of steepest ascent (increasing CR) from the origin for each
antimicrobial. Data were inspected to check whether the assumptions underlying
redundancy analysis were met. Signiﬁcance testing of multivariate models and
their factors (Supplementary Table 3) was done via permutation tests (1000
permutations), an approach robust to deviations from multivariate normality
and variance homogeneity; p < 0.05 was considered signiﬁcant. Analyses were
done in R76 using the Vegan work package78.
Data availability
Whole-genome sequencing data are available at NCBI (BioProject PRJNA419689). All
other relevant data are available within this article, the Supplementary Information, or
from the corresponding author upon request.
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